Crispr Therapeutics AG (CRSP) is a leader in gene editing, utilizing its proprietary CRISPR/Cas9 technology to innovate groundbreaking therapies for serious genetic diseases, including sickle cell disease and beta-thalassemia. Headquartered in Zug, Switzerland, the company is advancing a strong clinical pipeline with a focus on strategic collaborations designed to enhance the development and commercialization of its unique treatments. With robust potential for transformative patient outcomes and a commitment to addressing unmet medical needs, Crispr Therapeutics is positioned as a key player in the evolving landscape of biopharmaceuticals. Show more

Location: BAARERSTRASSE 14, ZUG, SWITZERLAND, 6300, Zug, 6300, USA | Website: https://www.crisprtx.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

4.761B

52 Wk Range

$30.04 - $78.48

Previous Close

$53.35

Open

$52.12

Volume

2,243,455

Day Range

$49.73 - $53.84

Enterprise Value

3.38B

Cash

286.5M

Avg Qtr Burn

-84.63M

Insider Ownership

1.58%

Institutional Own.

77.90%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CASGEVY™ (Exagamglogene autotemcel) (CTX001) (autologous CRISPR/Cas9 gene-edited hematopoietic stem cell therapy) (Exa-cel) Details Sickle cell disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CASGEVY™ (Exagamglogene autotemcel) (CTX001) (autologous CRISPR/Cas9 gene-edited hematopoietic stem cell therapy) Details Beta thalessemia	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Exagamglogene autotemcel (CTX001) (autologous CRISPR/Cas9 gene-edited hematopoietic stem cell therapy) Details Beta thalessemia	Phase 3 Interim Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Exagamglogene autotemcel (CTX001) (autologous CRISPR/Cas9 gene-edited hematopoietic stem cell therapy) Details Sickle cell disease	Phase 3 Interim Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SRSD107 Details VTE in patients undergoing total knee arthroplasty (TKA)	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX112 Details CD19+ malignancies, Blood cancer, Cancer, B-cell malignancies	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX110 (CD19) Details CD19+ malignancies, B-cell malignancies, Cancer, Blood cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX211 (formerly VCTX211) Details Type 1 diabetes	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX310 (ANGPTL3) Details Atherosclerotic cardiovascular disease	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX112 Details Systemic lupus erythematosus	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX130 (CD70) Details Blood cancer, Cancer, T-cell lymphoma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VCTX210 Details Type 1 diabetes	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zugocaptagene Geleucel/Zugo-Cel (CTX112) (CD19 CAR-T) Details Refractory Immune Thrombocytopenic Purpura And Warm Autoimmune Hemolytic Anemia	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX320 Lp(a) Details Atherosclerotic cardiovascular disease	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX460 Details Alpha-1 Antitrypsin Deficiency (AATD)	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX340 (AGT Gene Editing) Details Refractory Hypertension	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX321 (LPA Gene Editing) Details Elevated Lipoprotein(A)	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX450 (ALAS1 Gene Editing) Details Acute Hepatic Porphyria	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX120 (BCMA) Details Multiple myeloma, Blood cancer, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX131 (CD70) Details Cancer, Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.